Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine for diarrhea-dominant irritable bowel syndrome with elevated fecal calprotectin
IRCT20151106024901N5Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Mesalazine with Placebo (2 arms). Started Jan 2021; status: completed.
02
Drugs
Salcrozine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20151106024901N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151106024901N5.